← Search another drug
PatientPulse · by PatientPartner
Enhertu trastuzumab deruxtecan
High confidence
~55 public patient conversations and reviews analyzed (blogs, forums, review sites, clinical community posts)
Executive intelligence
The signal that moves starts & adherence
52%Positive sentiment in discussion
9,187FDA adverse-event reports
73%Flagged serious
88%Reports name female patients
ILD fear is the single biggest adherence threat: patients who understand the ILD monitoring protocol stay on therapy longer, making oncology-nurse and peer-education touchpoints the highest-leverage commercial investment.
- Efficacy belief is high and durable: patients describe liver-met disappearance and NEAD status sustaining hope through 10-plus cycles, making response visibility the top driver of adherence.
- Nausea-fatigue in the first two cycles is the primary abandonment window; patients who received proactive antiemetic protocols and dose-reduction conversations reported markedly better cycle-two persistence.
- ILD and pneumonitis generate disproportionate anxiety: caregivers and patients actively seek peer reassurance about cough surveillance, making this the sharpest unmet education gap in the corpus.
- Access and cost barriers, especially in the UK NHS and for off-label indications, are driving patients to crowdfunding and compassionate-use appeals, signaling a materially underserved patient-services opportunity.